🔥🐔 BizChicken 🐔🔥
Companies Similar to Apollomics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Alector, Inc.
AL001, AL101, AL002, AL003, AL044
Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.
About | Vision/Values | History | Leadership | Contact | Culture | Vision/Values | History | About | About | About | About | Careers | About | About
Symbol: ALEC
Recent Price: $1.72
Industry: Biotechnology
CEO: Dr. Arnon Rosenthal Ph.D.
Sector: Healthcare
Employees: 245
Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 415 231 5660
Leadership
- Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
- Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
- Marc Grasso, M.D., Chief Financial Officer
- Gary Romano, M.D., Ph.D., Chief Medical Officer
- Danielle Pasqualone, Ph.D., J.D., General Counsel
- Clare Hunt, M.B.A., Chief People Officer
- Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
- Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
- Norah Conway, Senior Vice President, Portfolio and Program Management
- Neil Berkley, M.S., M.B.A., Chief Business Officer
- Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
- Elizabeth Garofalo, M.D., Board Member
- Paula Hammond, Ph.D., Board Member
- Richard H. Scheller, Ph.D., Board Member
- David Wehner, Board Member
- Kristine Yaffe, M.D., Board Member
- Errol De Souza, Ph.D., Board Member
- Mark Altmeyer, M.B.A., Board Member
Last updated: 2024-12-31
Allarity Therapeutics, Inc.
Stenoparib, Dovitinib, IXEMPRA, Li Pla Cis, 2X-111
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing oncology therapeutics using companion diagnostics and drug response predictor technology.
Careers | Careers | Careers | About | About | About | About | About | About | About | About | Contact | Contact | Contact | Careers | About | About | About | About | About | About | About | About
Symbol: ALLR
Recent Price: $1.12
Industry: Biotechnology
CEO: Mr. Thomas H. Jensen
Sector: Healthcare
Employees: 5
Address: 210 Broadway, Cambridge, MA 02139
Phone: 401 426 4664
Last updated: 2024-12-31
Applied Therapeutics, Inc.
AT-007
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products targeting cardiovascular disease, galactosemia, and diabetic complications. Key products include AT-007 and AT-001.
About | Leadership | Leadership | Leadership | Leadership | Vision/Values | Culture | DEI | Contact | Contact | Careers | Careers | About | About | About
Symbol: APLT
Recent Price: $0.81
Industry: Biotechnology
CEO: Dr. Shoshana Shendelman Ph.D.
Sector: Healthcare
Employees: 31
Address: 545 Fifth Avenue, New York, NY 10017
Phone: 212 220 9226
Leadership
- Shoshana Shendelman, Chair, Board of Directors
- Riccardo Perfetti, Chief Medical Officer
- Les Funtleyder,
- Dale Hooks, Chief Commercial Officer
- Constantine Chinoporos, Chief Business Officer / Chief Operating Officer
- Joel Marcus,
- Jay Skyler,
- Stacy Kanter,
- Teena Lerner,
- Donald Landry M.D., Ph.D., Chair, Scientific Advisory Board
- Roy Freeman M.D.,
- Roxana Mehran M.D.,
- Lawrence Steinman M.D.,
- Gregg Stone M.D.,
- Donald d'Amico M.D.,
- Donald Landry, Chair, Scientific Advisory Board
- Roy Freeman,
- Roxana Mehran,
- Lawrence Steinman,
- Gregg Stone,
- Donald d'Amico,
Last updated: 2024-12-31
Elicio Therapeutics, Inc.
ELI-002
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.
Symbol: ELTX
Recent Price: $5.00
Industry: Biotechnology
CEO: Mr. Robert T. Connelly
Sector: Healthcare
Employees: 32
Address: 451 D Street, Boston, MA 02210
Phone: 857-209-0050
Last updated: 2024-12-31
Lyell Immunopharma, Inc.
LYL797, LYL845, NY-ESO-1
Lyell Immunopharma, Inc. is a biopharmaceutical company developing T cell therapies focused on treating patients with solid tumors using advanced genetic and epigenetic reprogramming technologies.
About | Our Story | Vision/Values | Our Story | Leadership | Contact | Contact | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About
Symbol: LYEL
Recent Price: $0.62
Industry: Biotechnology
CEO: Dr. Lynn Seely M.D., Ph.D.
Sector: Healthcare
Employees: 224
Address: 201 Haskins Way, South San Francisco, CA 94080
Phone: 650 695 0677
Leadership
- Lynn Seely, M.D., President & Chief Executive Officer
- Stephen Hill, Chief Operating Officer
- Matthew Lang, J.D., Chief Business Officer
- Gary Lee, Ph.D., Chief Scientific Officer
- Charles Newton, Chief Financial Officer
- Ellen Rose, Senior Vice President, Investor Relations and Communications
- Bryan Selby, Senior Vice President, Clinical Development Operations
- Ann Tomlin, Senior Vice President, Human Resources
- Rick Klausner, M.D., Founder & Board Chair
- Crystal Mackall, M.D., Founder
- Stan Riddell, M.D., Founder
- Hans Bishop, Director
- Otis Brawley, M.D., Director
- Catherine Friedman, Director
- Elizabeth Nabel, M.D., Director
- Robert Nelsen, Director
- William Rieflin, Director
Last updated: 2024-12-31
Oncternal Therapeutics, Inc.
zilovertamab, ONCT-216, ONCT-808, ONCT-534
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.
Symbol: ONCT
Recent Price: $0.53
Industry: Biotechnology
CEO: Dr. James B. Breitmeyer M.D., Ph.D.
Sector: Healthcare
Employees: 27
Address: 12230 El Camino Real, San Diego, CA 92130
Phone: 858 434 1113
Last updated: 2024-12-31
Pyxis Oncology, Inc.
PYX-106, PYX-102, PYX-201, PYX-202, PYX-203
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, focuses on developing therapies to treat various cancers through immune-oncology and antibody drug conjugate product candidates.
Symbol: PYXS
Recent Price: $1.56
Industry: Biotechnology
CEO: Dr. Lara S. Sullivan M.D., MBA
Sector: Healthcare
Employees: 55
Address: 35 Cambridgepark Drive, Cambridge, MA 02140
Phone: 617 221 9059
Last updated: 2024-12-31
Scholar Rock Holding Corporation
Apitegromab
Scholar Rock Holding Corporation is a biopharmaceutical company focused on developing medicines for serious diseases where protein growth factor signaling plays a critical role. The company advances Apitegromab, targeting spinal muscular atrophy, and SRK-181 for cancer treatments, alongside a pipeline addressing neuromuscular disorders, cancer, and fibrosis.
About | About | About | News | Events | ESG | About | About | About | Careers | About | About | Leadership | Directors | About | Contact | Contact | Careers
Symbol: SRRK
Recent Price: $42.91
Industry: Biotechnology
CEO: Dr. Jay Thomas Backstrom M.D., M.P.H.
Sector: Healthcare
Employees: 150
Address: 301 Binney Street, Cambridge, MA 02142
Phone: 857 259 3860
Leadership
- David Hallal, Chairman of the Scholar Rock Board and Chief Executive Officer of ElevateBio
- Srini Akkaraju, MD, PhD, Founder & Managing Partner, Samsara BioCapital
- Jay Backstrom, M.D., MPH, President & CEO
- Richard Brudnick, Chief Business Officer, Prime Medicine
- Kristina Burow, Managing Director, ARCH Venture Partners
- Jeffrey Flier, MD, Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor; Former Dean of Harvard Medical School
- Michael Gilman, PhD, CEO, Arrakis Therapeutics
- Katie Peng, Chief Commercial Officer, Denali Therapeutics
- Joshua Reed, Chief Financial Officer of Omega Therapeutics
- Akshay Vaishnaw, MD, PhD, Chief Innovation Officer, Alnylam Pharmaceuticals
Last updated: 2024-12-31
Acrivon Therapeutics, Inc. Common Stock
Acrivon Predictive Precision Proteomics
Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines using a proteomics-based platform to identify patient responders. Their lead candidate, ACR-368, is in Phase 2 trials for various cancers.
Symbol: ACRV
Recent Price: $5.41
Industry: Biotechnology
CEO: Dr. Peter Blume-Jensen M.D., Ph.D.
Sector: Healthcare
Employees: 58
Address: 480 Arsenal Way, Watertown, MA 02472
Phone: 617-207-8979
Last updated: 2024-12-31
ALX Oncology Holdings Inc.
ALX148
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies for cancer patients. Its lead product, ALX148, targets CD47 and is in trials for various cancers. The company also explores pre-clinical treatments like ALTA-002 to enhance immune response to cancer.
About | Contact | About | About | Careers | Careers | Jobs | Jobs | Jobs | Jobs | Careers | About | About | Careers | Jobs
Symbol: ALXO
Recent Price: $1.66
Industry: Biotechnology
CEO: Mr. Jason W. Lettmann
Sector: Healthcare
Employees: 81
Address: 323 Allerton Avenue, South San Francisco, CA 94080
Phone: 650 466 7125
Last updated: 2024-12-31
Apogee Therapeutics, Inc.
APG777, APG808, APG990, APG222
Apogee Therapeutics, Inc. is a biotechnology company developing biologics for the treatment of atopic dermatitis, COPD, and related inflammatory and immunology conditions. Founded in 2022 and based in Waltham, Massachusetts.
Symbol: APGE
Recent Price: $44.64
Industry: Biotechnology
CEO: Dr. Michael Thomas Henderson M.D.
Sector: Healthcare
Employees: 91
Address: 221 Crescent Street, Waltham, MA 02453
Phone: 650-394-5230
Last updated: 2024-12-31
Apollomics, Inc.
APL-101 (Vebreltinib), APL-102, APL-122
Apollomics, Inc. is a biotechnology company that discovers and develops oncology therapies to address unmet medical needs, focusing on treatments for non-small cell lung cancer, liver cancer, breast cancer, esophageal cancer, and brain tumors.
Symbol: APLM
Recent Price: $10.13
Industry: Biotechnology
CEO: Dr. Guo-Liang Yu Ph.D.
Sector: Healthcare
Employees: 45
Address: 989 East Hillsdale Blvd, Foster City, CA 94404
Phone: 650 209 4055
Last updated: 2024-12-31
Apellis Pharmaceuticals, Inc.
pegcetacoplan
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds targeting the complement system for autoimmune and inflammatory diseases.
About | Leadership | Directors | About | About | Contact | Contact | Contact | Culture | Benefits | Careers | Careers | About | About
Symbol: APLS
Recent Price: $31.90
Industry: Biotechnology
CEO: Dr. Cedric Francois M.D., Ph.D.
Sector: Healthcare
Employees: 702
Address: 100 Fifth Avenue, Waltham, MA 02451
Phone: 617 977 5700
Leadership
- Cedric Francois, MD, PhD, Co-Founder & Chief Executive Officer/President
- Caroline Baumal, MD, Chief Medical Officer
- Mark DeLong, Chief Business & Strategy Officer
- Pascal Deschatelets, PhD, Co-Founder & Chief Scientific Officer
- Jeffrey Eisele, PhD, Chief Development Officer
- Karen Lewis, Chief People Officer
- Nur Nicholson, Chief Technical Operations Officer
- Timothy Sullivan, Chief Financial Officer
- Adam Townsend, Chief Operating Officer
- David Watson, JD, General Counsel
- Apellis Pharmaceuticals,
- Gerald Chan, Chairman
- Sinclair Dunlop, Director
- Stephanie Monaghan O’Brien, Director
- Paul Fonteyne, Director
- Cedric Francois, Co-Founder & Chief Executive Officer/President
- Alec Machiels, Co-Founder
Last updated: 2024-12-31
bluebird bio, Inc.
betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel
bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.
About | Leadership | DEI | About | About | About | Contact | Careers | About | About | About | About
Symbol: BLUE
Recent Price: $7.86
Industry: Biotechnology
CEO: Mr. Andrew Obenshain
Sector: Healthcare
Employees: 375
Address: 60 Binney Street, Cambridge, MA 02142
Phone: 339 499 9300
Leadership
- Sarah Alspach, Senior Vice President, External Affairs
- Rich Colvin, MD, PhD, Chief Medical Officer
- Kasra Kasraian, Senior Vice President, Technical Development and Operations
- Tom Klima, Chief Commercial & Operating Officer
- Andrew Obenshain, Chief Executive Officer
- Scott Shoemaker, Senior Vice President, Quality
- James Sterling, Chief Financial Officer
- Joe Vittiglio, Chief Business and Legal Officer
- Andrea Walton, Chief People Officer
- Leslie Wilder, Vice President, Head of Regulatory Science
- Mark Vachon, Chairman; Formerly of GE
- John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
- Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
- Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
- Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
- Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
- Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
- Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare
Last updated: 2024-12-31
BeyondSpring Inc.
Plinabulin
Beyond Spring Inc. is a clinical stage biopharmaceutical company focused on developing cancer therapies, including its lead asset Plinabulin, which is in advanced clinical trials.
Contact | Careers | Careers | About | Leadership | About | Directors | Careers | Careers | Careers | Careers | Careers | Careers | About | About
Symbol: BYSI
Recent Price: $1.62
Industry: Biotechnology
CEO: Dr. Lan Huang Ph.D.
Sector: Healthcare
Employees: 36
Address: 28 Liberty Street, New York, NY 10005
Phone: 646 305 6387
Last updated: 2024-12-31
Celularity Inc.
CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.
About | Leadership | Directors | About | About | About | About | Directors | Careers | About | About | About | About | About | About
Symbol: CELU
Recent Price: $2.05
Industry: Biotechnology
CEO: Dr. Robert Joseph Hariri M.D., Ph.D.
Sector: Healthcare
Employees: 120
Address: 170 Park Avenue, Florham Park, NJ 07932
Phone: 908 768 2170
Leadership
- Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
- David Beers, CFA, Chief Financial Officer
- Stephen Brigido, DPM, President, Degenerative Diseases
- John Haines, Global Manager and Chief Administrative Officer
- K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
- John Colerangle, DVM, Ph.D., Regulatory Affairs
- Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
- Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
- Carmine Palummo, Corporate Operations
- Tim Wilk, Technical Operations
- Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
- Peter Diamandis, M.D., Director
- Dean Kehler, Director
- Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
- Diane Parks, Director
Last updated: 2024-12-31
Nuvalent, Inc.
NVL-520 and NVL-655
Nuvalent, Inc. is a clinical stage biopharmaceutical company that develops therapies for patients with cancer, focusing on brain-penetrant inhibitors for ROS1 and ALK.
Symbol: NUVL
Recent Price: $77.87
Industry: Biotechnology
CEO: Dr. James R. Porter Ph.D.
Sector: Healthcare
Employees: 115
Address: One Broadway, Cambridge, MA 02142
Phone: 857 357 7000
Last updated: 2024-12-31
Pliant Therapeutics, Inc.
PLN-74809
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Their lead product candidate, PLN-74809, is currently in Phase 2a trials.
Symbol: PLRX
Recent Price: $12.79
Industry: Biotechnology
CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Sector: Healthcare
Employees: 166
Address: 260 Littlefield Avenue, South San Francisco, CA 94080
Phone: 650 481 6770
Last updated: 2024-12-31
Abeona Therapeutics Inc.
EB-101
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.
Symbol: ABEO
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.
Sector: Healthcare
Employees: 84
Address: 1330 Avenue of the Americas, New York, NY 10019
Phone: 646 813 4701
Last updated: 2024-12-31
Aptevo Therapeutics Inc.
APVO436
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapeutic candidates to treat various forms of cancer, with a primary focus on APVO436, a bispecific T-cell engaging antibody for leukemia and myelodysplastic syndrome.
About | Leadership | Directors | About | Contact | About | Contact | Contact | Contact | About | Leadership | Directors | About | About | About | About | About | About | About | About | About | About | About
Symbol: APVO
Recent Price: $4.78
Industry: Biotechnology
CEO: Mr. Marvin L. White
Sector: Healthcare
Employees: 40
Address: 2401 4th Avenue, Seattle, WA 98121
Phone: 206 838 0500
Leadership
- Marvin L. White, President and Chief Executive Officer
- Jeff Lamothe, EVP and Chief Operating Officer
- Daphne Taylor, SVP and Chief Financial Officer
- Dirk Huebner, M.D., Chief Medical Officer
- SoYoung Kwon, SVP, General Counsel, Business Development and Corporate Affairs
Last updated: 2024-12-31